James Gardner
General Practice · Greenbrae, CANPI 1255447330
Payments from drug & device makers
Across 79 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$563
- Teva Pharmaceuticals USA, Inc.$137
- Amgen$121
- Novo Nordisk$118
- Endo Pharmaceuticals Inc.$112
- Astellas Pharma US Inc$107
- plus $536 from 15 others
What the payments were for
- Food & beverage$1,50189%
- Education$19311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $563 |
| Teva Pharmaceuticals USA, Inc. | 7 | $137 |
| Amgen | 2 | $121 |
| Novo Nordisk | 1 | $118 |
| Endo Pharmaceuticals Inc. | 5 | $112 |
| Astellas Pharma US Inc | 3 | $107 |
| Lilly USA, LLC | 4 | $81 |
| Pfizer | 5 | $75 |
| Biomarin Pharmaceutical Inc. | 2 | $68 |
| Amarin Pharma, Inc. | 2 | $46 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| AMAG Pharmaceuticals, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Boston Scientific | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Merck | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$102
How this compares
$1,695 in reported general payments places this provider in the 85th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 13 | $5,386 |
| ProgesteroneProgesterone, Micronized | 62 | $2,024 |
| Liothyronine Sodium | 52 | $1,903 |
| SynthroidLevothyroxine Sodium | 17 | $1,552 |
| Levothyroxine Sodium | 112 | $1,469 |
| Armour ThyroidThyroid,pork | 19 | $1,393 |
| Rosuvastatin Calcium | 51 | $1,210 |
| Testosterone Cypionate | 33 | $1,017 |
| Celecoxib | 41 | $979 |
| Triazolam | 13 | $937 |
| Oxycodone Hcl | 19 | $881 |
| Bupropion XlBupropion Hcl | 28 | $862 |
| Omeprazole | 25 | $623 |
| ValacyclovirValacyclovir Hcl | 11 | $592 |
| Atorvastatin Calcium | 43 | $574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckBelsomra | $20 | $5,38613 claims |
| AbbVieSynthroid, Armour Thyroid | $563 | $2,94536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 12,963 general practice providers in California.
Other general practice in Greenbrae
- Marc GeissbergerGreenbrae$583K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.